论文部分内容阅读
用抗膀胱癌免疫毒素（BDI-1-MD）行膀胱癌灌注20例，治疗膀胱癌及预防膀胱癌复发，其中16例（Ⅰ组）于术后进行灌注，4例多发性膀胱肿瘤（Ⅱ组）直接行灌注。Ⅰ组中，膀胱肿瘤Ⅰ级4例，Ⅰ～Ⅱ级5例，Ⅱ级4例，Ⅱ～Ⅲ级3例。初发肿瘤13例，复发肿瘤3例。Ⅱ组中，Ⅲ～Ⅲ级1树，Ⅲ级3例。初发肿瘤3例，复发肿瘤1例。平均随访12．3个月，Ⅰ组仅1例8个月后复发（复发率6．3％）。Ⅱ组中，有效2例，弱效2例。未见灌注引起的毒副反应，免疫指标无异常。表明BDI-1-MD对膀胱肿瘤有强杀伤能力和高度特异性，而对正常组织无损伤。提示此免疫毒素对治疗膀胱癌及预防术后复发有良好的作用。
20 patients with bladder cancer were treated with anti-bladder cancer immunotoxin (BDI-1-MD) to treat bladder cancer and prevent recurrence of bladder cancer. 16 patients (group I) were perfused postoperatively and 4 patients had multiple bladder tumors (II) Group) Direct perfusion. In group I, there were 4 cases of bladder tumor grade I, 5 cases of grade I-II, 4 cases of grade II, and 3 cases of grade II-III. There were 13 primary tumors and 3 recurrent tumors. In group II, there were 1 tree in grades III to III and 3 in grade III. There were 3 primary tumors and 1 recurrent tumor. After a mean follow-up of 12.3 months, only one patient in group I relapsed after 8 months (recurrence rate was 6.3%). In group II, 2 were effective and 2 were weak. No side effects caused by perfusion were observed, and there was no abnormal immune index. It was shown that BDI-1-MD has strong killing capacity and high specificity for bladder tumors, but no damage to normal tissues. It is suggested that this immunotoxin has a good effect on the treatment of bladder cancer and prevention of postoperative recurrence.